Montelukast (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma and allergic rhinitis in adults and children, providing maintenance therapy and relief from exercise‑induced bronchoconstriction.

GNH USA supplies Montelukast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards for global distribution.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation.

Asthma: improves long‑term control and reduces frequency of exacerbations in maintenance therapy. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry cough. - Nausea: feeling of queasiness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Allergic reactions: rash, swelling, or anaphylaxis. - Neuropsychiatric events: mood changes, depression, or suicidal thoughts. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.

When prescribing Montelukast, clinicians should consider several safety precautions. - Assess asthma control: ensure patient is on appropriate rescue medication before initiating. - Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be required in patients with liver disease. - Not for acute asthma attacks: should not replace short‑acting bronchodilators during emergencies. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower montelukast plasma levels. - Phenobarbital: accelerates metabolism, reducing therapeutic effect. - Ketoconazole: potent CYP3A4 inhibitor, may increase exposure and risk of side effects.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition, may raise drug concentrations. - Oral contraceptives: montelukast may increase hormone levels; monitor for side effects. - Other leukotriene modifiers (e.g., zafirlukast): combined use may increase risk of liver enzyme elevation. - NSAIDs: monitor for additive gastrointestinal discomfort.